E. Claire Dees

TL;DR: Basal-like and HER2+/ER− subtypes are more sensitive to anthracycline-based neoadjuvant chemotherapy than luminal breast cancers and could be explained by a higher likelihood of relapse in patients in whom pathologic complete response was not achieved.

TL;DR: Lapatinib was well tolerated at doses ranging from 500 to 1,600 mg once daily and clinical activity was observed in heavily pretreated patients with ErbB1-expressing and/or ErbbB2-overexpressing metastatic cancers, including four PRs in patients with trastuzumab-resistant breast cancers and prolonged stable disease in 10 patients.

TL;DR: Ongoing preclinical evaluations of the mechanisms that underlie the antitumor effects of proteasome inhibitors, and clinical trials in a variety of tumor types, will allow additional refinement of the role these agents will play in cancer therapy.

TL;DR: Preliminary evidence of biologic and clinical activity in ErbB1 and/or Erb B2-overexpressing tumors is exhibited, however, the limited sample size of this study and the variability of the biologic endpoints suggest that further work is needed to prioritize biomarkers for disease-directed studies, and underscores the need for improved trial design strategies in early clinical studies of targeted agents.

TL;DR: Bortezomib/PegLD was safely administered in this study with promising antitumor activity, supporting further testing of this regimen and pharmacokinetic and pharmacodynamic studies did not find significant drug interactions between these agents.